IL37 and psoriasis 14, pustular: Among the GPP patients, IL-17 inhibition led to higher rates of GPPASI 90 (IL-17 70% vs. IL-23 22%, p = 0.022) and GPPASI 100 responses at week 12 (IL-17 56% vs. IL-23 11%, p = 0.019) and GPPASI 90 responses at week 24 (IL-17 63% vs. IL-23 56%, p = 0.999).